Early Intensive Lipid-Lowering With Inclisiran for Plaque Stabilization in Acute Coronary Syndrome

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 294 participants.

Also called NCT07799779

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 294 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07799779
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07799779. Randomized; single masking; primary purpose treatment. Start 2026-11-30 (anticipated); primary completion 2029-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Early Intensive Lipid-Lowering With Inclisiran for Plaque Stabilization in Acute Coronary Syndrome
Acronym
SEsiR-ACS
Condition
Acute Coronary Syndromes (ACS)
Intervention (Drug)
Inclisiran
Intervention (Drug)
Atorvastatin or Rosuvastatin
Intervention (Drug)
Ezetimibe
Lead sponsor
Seoul National University Bundang Hospital (class: other)
Collaborator
Dotter Co., Ltd. (class: not stated)
Collaborator
Novartis Korea Ltd. (class: industry)
Collaborator
Hanmi Pharmaceutical co., ltd. (class: other)

Record details

Record id
cardio:ct-nct07799779
Content hash
8cd0e11dbe63ce9b164ef13ff55d0eb23fe85176e72b17100c59511d6061d650